Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertumaxomab in HER2-low Advanced Breast Cancer
NCT00452140Phase 2
Key facts
- Status
- Terminated
- Start
- Mar 2007
- Countries
- 5
- Sponsor
- Neovii Pharmaceuticals
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Drugs
- ertumaxomab
- Conditions
- breast cancer
01
Overview
Phase 2, open-label, single-arm trial of ertumaxomab in breast cancer, sponsored by Neovii Pharmaceuticals. Primary endpoint: Objective Response Rate. Started Mar 2007; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Ertumaxomab
Ertumaxomab 10 µg (day 0) then 100 µg weekly
03
Endpoints
Primary
Objective Response Rate
Secondary
Clinical Benefit Rate
Duration of Response
Time to Progression
Adverse Events
Human Anti-Murine Antibodies
Vital Signs
Laboratory Parameters
Beyond the preview
Go deeper on NCT00452140.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00452140.